Review
Oncology
Brigida Anna Maiorano, Martina Catalano, Evaristo Maiello, Giandomenico Roviello
Summary: Enfortumab vedotin (EV) is a promising treatment for metastatic urothelial carcinoma (mUC), showing good efficacy and survival improvement in a setting with limited treatment options. It has the potential to become an effective treatment option for mUC patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, General & Internal
Thomas Powles, Jonathan E. Rosenberg, Guru P. Sonpavde, Yohann Loriot, Ignacio Duran, Jae-Lyun Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Chunzhang Wu, Mary Campbell, Maria Matsangou, Daniel P. Petrylak
Summary: Enfortumab vedotin significantly prolonged survival compared with standard chemotherapy in patients with advanced urothelial carcinoma who had previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor, as well as showing better progression-free survival outcomes.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Catherine C. Fahey, Caroline A. Nebhan, Sally York, Nancy B. Davis, Paula J. Hurley, Jennifer B. Gordetsky, Kerry R. Schaffer
Summary: Penile squamous cell carcinoma is a rare disease with limited treatment options, especially in the metastatic setting. This case report highlights the potential of using the Nectin-4 inhibitor enfortumab-vedotin-ejfv (EV) as a treatment option for metastatic penile squamous cell carcinoma. Further studies are needed to establish high-quality evidence for guiding treatment decisions in this disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Vadim S. Koshkin, Nicholas Henderson, Marihella James, Divya Natesan, Dory Freeman, Amanda Nizam, Christopher T. Su, Ali Raza Khaki, Chelsea K. Osterman, Michael J. Glover, Ryan Chiang, Dimitrios Makrakis, Rafee Talukder, Emily Lemke, T. Anders Olsen, Jayanshu Jain, Albert Jang, Alicia Ali, Tanya Jindal, Jonathan Chou, Terence W. Friedlander, Christopher Hoimes, Arnab Basu, Yousef Zakharia, Pedro C. Barata, Mehmet A. Bilen, Hamid Emamekhoo, Nancy B. Davis, Sumit A. Shah, Matthew I. Milowsky, Shilpa Gupta, Matthew T. Campbell, Petros Grivas, Guru P. Sonpavde, Deepak Kilari, Ajjai S. Alva
Summary: Enfortumab vedotin has shown consistent responses in a large retrospective cohort, including patients with variant histology, FGFR3 alterations, and previously excluded patients with comorbidities and low estimated glomerular filtration rates. The drug has been effective in treating a wide range of patient populations, replicating previously reported clinical trial data in a real-world setting.
Article
Oncology
Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E. Dorff, Yutao Gong, Vicky Hsu, Fang Li, Tiffany K. Ricks, Pengfei Song, Shenghui Tang, Peter E. Waldron, Jingyu Yu, Eias Zahalka, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Amna Ibrahim, Julia A. Beaver
Summary: Enfortumab vedotin-ejfv has been granted accelerated approval by the FDA for the treatment of locally advanced or metastatic urothelial cancer. The drug showed certain efficacy in clinical trials but also comes with a high rate of adverse reactions. This approval is subject to further verification and description of clinical benefits in confirmatory trials.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Takashi Kawahara, Akihito Hasizume, Koichi Uemura, Katsuya Yamaguchi, Hiroki Ito, Teppei Takeshima, Hisashi Hasumi, Jun-ichi Teranishi, Kimito Ousaka, Kazuhide Makiyama, Hiroji Uemura
Summary: An analysis of 6007 patients with urothelial cancer treated with pembrolizumab showed that continuing treatment with enfortumab vedotin resulted in longer overall survival compared to switching to paclitaxel/docetaxel, offering better survival prospects for Japanese patients.
Article
Oncology
Shinji Tamada, Daiki Ikarashi, Naoki Yanagawa, Moe Toyoshima, Kenta Takahashi, Tomohiko Matsuura, Shigekatsu Maekawa, Renpei Kato, Mitsugu Kanehira, Ryo Takata, Wataru Obara
Summary: We report a rare case of a patient with advanced bladder cancer who developed sigmoidorectal fistula after treatment with enfortumab vedotin. The study found that enfortumab vedotin was remarkably effective in shrinking lung metastases and local recurrent lesion, but also resulted in the formation of sigmoidorectal fistula. Immunohistochemical analysis showed increased nectin-4 expression.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Moritz Maas, Viktoria Stuehler, Simon Walz, Arnulf Stenzl, Jens Bedke
Summary: Enfortumab vedotin has shown promising efficacy and good tolerability in phase I/II trials, particularly in heavily treated patients and those with liver metastases. It seems to be more effective than third-line chemotherapies, with ongoing studies to determine its potential in treatment sequences.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Article
Oncology
Charlene M. Mantia, Guru Sonpavde
Summary: Enfortumab vedotin-ejfv has shown promising efficacy and safety in pretreated patients with advanced urothelial carcinoma, and currently being evaluated in clinical trials in earlier lines of treatment and in combination therapy.
EXPERT REVIEW OF ANTICANCER THERAPY
(2022)
Review
Biotechnology & Applied Microbiology
Jean Hoffman-Censits, Laneisha Maldonado
Summary: Enfortumab vedotin (EV) is a novel antibody-drug conjugate that has been FDA-approved for the treatment of treatment-refractory urothelial cancer. It has shown high activity in patients with poor prognosis, and has a good tolerability profile. Ongoing trials are exploring its use in different disease states and in combination with other agents.
ONCOTARGETS AND THERAPY
(2022)
Article
Oncology
Catherine Curran, Elio Adib, Vera Kazakova, Petros Grivas, Leonidas Nikolaos Diamantopoulos, Ajjai Shivaram Alva, Christopher Su, Rohit K. Jain, Ankita Tandon, Andrea Necchi, Laura Marandino, Trisha M. Plastini, Jaime R. Merchan, Guru Sonpavde
Summary: This retrospective study highlights the poor outcomes of metastatic urothelial carcinoma patients following discontinuation of Enfortumab Vedotin (EV), with only 51% receiving therapy after discontinuation. It also identifies benchmarks for evaluating the activity of new agents after EV and suggests that the duration of EV may be a potential prognostic factor following discontinuation.
CLINICAL GENITOURINARY CANCER
(2022)
Review
Oncology
Mario E. Lacouture, Anisha B. Patel, Jonathan E. Rosenberg, Peter H. O'Donnell
Summary: Enfortumab vedotin is an antibody-drug conjugate that targets Nectin-4 and has been approved by the US FDA for the treatment of locally advanced or metastatic urothelial cancer. It has shown a survival benefit compared to chemotherapy in patients previously treated with other therapies. However, it may cause severe cutaneous adverse reactions.
Article
Oncology
Jean Hoffman-Censits, Kara Lombardo, David McConkey, Noah M. Hahn, Babar Bashir, Wm Kevin Kelly, Burles Johnson, Andres Matoso
Summary: Enfortumab vedotin (EV) is a newly approved drug for platinum-and checkpoint-refractory urothelial cancer, with a high response rate. However, not all patients benefit from this treatment, and the mechanisms of treatment resistance remain unclear. Additional research is needed to further understand the response to EV therapy.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Oncology
Peter H. O'Donnell, Matthew I. Milowsky, Daniel P. Petrylak, Christopher J. Hoimes, Thomas W. Flaig, Nataliya Mar, Helen H. Moon, Terence W. Friedlander, Rana R. McKay, Mehmet A. Bilen, Sandy Srinivas, Earle F. Burgess, Chethan Ramamurthy, Saby George, Daniel M. Geynisman, Sergio Bracarda, Delphine Borchiellini, Lionnel Geoffrois, Jose Pablo Maroto Rey, Christiano Ferrario, Anne-Sophie Carret, Yao Yu, Maria Guseva, Blanca Homet Moreno, Jonathan E. Rosenberg
Summary: EV + Pembro demonstrated a high confirmed objective response rate (cORR) with durable responses as a first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC). Patients who received EV monotherapy had a response and safety profile consistent with previous studies. Adverse events for EV + Pembro were manageable, with no new safety signals observed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Kaylyn R. Collette, Zin W. Myint, Saurabh V. Parasramka, Carleton S. Ellis
Summary: The clinical management of metastatic urothelial carcinoma has been significantly improved with the emergence of monoclonal antibodies and antibody-drug conjugates. This case report presents a patient on peritoneal dialysis who showed an impressive response to Enfortumab vedotin without significant toxicity.
FRONTIERS IN ONCOLOGY
(2022)
Article
Chemistry, Physical
Ye Xu, Fang Jin, Guiying Wu, Tao Wang, Jingchao Zhang, Yanjun Chen
Summary: The borosilicate zeolite ERB-1 was modified by loading titanium and changing its polarity to improve its catalytic activity in aqueous solutions. The modified Ti-ERB-1 showed significantly improved catalytic activity in the presence of H2O2 oxidant.
Article
Statistics & Probability
Jingfei Zhang, Will Wei Sun, Lexin Li
Summary: In this article, a new generalized matrix response regression model is proposed for the analysis of multiple-subject network data. The model characterizes the connectivity pattern of the network data and the effect of subject covariates through a low-rank intercept matrix and a sparse slope tensor, respectively. An efficient parameter estimation algorithm is developed, and an error bound for the estimator's accuracy is established. The efficacy of the method is demonstrated through simulations and brain connectivity studies.
JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS
(2023)
Article
Chemistry, Medicinal
Jingjing Zhang, Hualing Zhu, Lixia Xiong, Jun Shi, Zhiqiang Huang
Summary: By designing and synthesizing benzoylureas analogues with carbamate groups, it was found that these compounds exhibited good larvicidal activities against a broad spectrum of insects such as oriental armyworm, diamondback moth, and mosquito. One compound (3g) showed the highest insecticidal activity against oriental armyworm.
LETTERS IN DRUG DESIGN & DISCOVERY
(2023)
Article
Chemistry, Physical
Yuzhao Ouyang, Decai Zhu, Chengjun Zhu, Yingbo Zhang, Jiamei Liu, Xin Jia, Jie Yu, Xinfang Li, Min Yang, Xiaowei Gao
Summary: This study reports a new Ruddlesden-Popper (R-P) structure oxide, which is widely used as the electrode material in low temperature solid oxide fuel cells (LT-SOFCs) due to its high catalytic activity and excellent oxygen transport performance. However, there are few reports on its application as the electrolyte material in LT-SOFCs. The researchers prepared a P-N heterostructure by using R-P P-type semiconductor Sm1.2Sr0.8Ni0.6Fe0.4O4+5 (SSNF) oxide material as the electrolyte and N-type semiconductor Sm0.075Nd0.075Ce0.85O2-5 (SNDC) oxide material as the cathode. The 5SSNF-5SNDC composite electrolyte exhibited a high ionic conductivity of 0.201 S.cm-1 and a remarkable fuel cell power density of 1056 mW.cm-2 at 550℃. The results indicate that P-N heterojunctions constructed from oxide materials with highly catalytically active R-P structures exhibit excellent electrolyte performance. This work provides a new perspective for developing advanced electrolytes of LT-SOFCs.
INTERNATIONAL JOURNAL OF HYDROGEN ENERGY
(2023)
Article
Oncology
Chao Xu, Xiaoli Xie, Ning Kang, Huiqing Jiang
Summary: The study investigated the efficacy and safety of neoadjuvant S-1 plus oxaliplatin combined with PD-1 inhibitor and apatinib (SOXPA) in locally advanced gastric cancer (LAGC) patients. The results showed that this treatment achieved satisfactory clinical response, pathological response, survival profile, and manageable safety in LAGC patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Meghan K. Thomas, Marc E. Heincelman, Jingwen Zhang, Justin Marsden, Jennifer Dulin, Patrick Robbins, Kelly Hunt, Patrick Mauldin, William P. Moran, Benjamin Kalivas
Summary: Patients admitted via interhospital transfer are more likely to experience in-hospital delirium, leading to increased mortality, length of stay, and discharge to facility. Routine screening and intervention prior to patient transfer are emphasized.
JOURNAL OF INVESTIGATIVE MEDICINE
(2023)
Article
Thermodynamics
Ning Qian, Fan Jiang, Marco Marengo, Jiajia Chen, Yucan Fu, Jingzhou Zhang, Jiuhua Xu
Summary: This study investigates the start-up behavior of oscillating heat pipes (OHP) under axial-rotation and highlights the importance of start-up speed on grinding efficiency and quality. It is found that OHP filled with acetone has the shortest start-up time, and the cold air pressure and centrifugal acceleration significantly affect the start-up time.
APPLIED THERMAL ENGINEERING
(2023)
Article
Fisheries
Pingping Li, Haihong Chen, Jingyu Zhang, Xiaoqing Feng, Baoheng Xiao, Yiyi Hu, Zhenghong Sui
Summary: In recent years, changes in the concentrations and compositions of nutrients in the ocean have negatively affected the biomass and quality of macroalgae. A strain of Gracilariopsis lemaneiformis with a curly branch phenotype has been discovered in China, causing negative impacts on the cultivation industry. The abnormality of this strain is correlated with the concentration of nitrogen and phosphorus, and certain biological processes are down-regulated compared to the normal strain.
Article
Cell Biology
Shuang Hao, Jingchao Zhang, Yu Pei, Longhui Guo, Zhenxing Liang
Summary: This study found that epicardial adipose tissue (EAT) mediates cardiomyocyte apoptosis after acute myocardial infarction (MI) through secretion of complement factor D (CFD) and activation of PARP-1 activity. This discovery offers key targets for intervention in acute MI.
CELLULAR SIGNALLING
(2023)
Article
Thermodynamics
Yuan-wei Lyu, Yun-duo Zhao, Jing-zhou Zhang, Jing-yang Zhang, Yong Shan
Summary: In this study, impinging heat transfer by a synthetic jet induced by a planar lobed orifice on a flat plate and a semi-cylindrical concave plate is investigated by means of Large Eddy Simulation. The results show that the temperature variation is primarily affected by the restriction of the target plate and the recirculation zone of the concave plate.
INTERNATIONAL JOURNAL OF THERMAL SCIENCES
(2023)
Article
Chemistry, Physical
Shuxiang Wen, Xin Li, Jingjing Zhang, Jie Wang, Hao Ding, Ningshuang Zhang, Dongni Zhao, Liping Mao, Shiyou Li
Summary: This study investigates the compatibility of Na2Ti3O7@C anode material with sodium perchlorate (NaClO4)-based and sodium trifluoromethyl sulfonate (NaCF3SO3)-based electrolytes in sodium ion batteries (SIBs). The results reveal that the NaCF3SO3-based electrolyte forms a thin, compact, and uniform solid electrolyte interphase (SEI) film, which reduces the transmission energy barrier of Na+ and improves the cycling and rate performance of batteries. In contrast, the NaClO4-based electrolyte leads to the formation of a thicker SEI film containing Na(2)CO(3) and NaF, resulting in higher interface impedance and decreased battery cycle performance.
JOURNAL OF ALLOYS AND COMPOUNDS
(2023)
Article
Chemistry, Medicinal
Si-Wei Wang, Shu-Yu Xu, Tian Gan, Xiao-Bin Zhang, Jia-Hong Li, Xing Wang, He-Zhong Jiang
Summary: This study analyzed the chemical composition of Lindera fragrans leaf ethanol extract using UPLC-Q-Orbitrap HRMS technology. The extract was found to contain approximately 22 compounds and showed significant antidepressant activity in mice with chronic unpredictable mild stress-induced depression, improving behavioral indexes and regulating levels of CORT, 5-HT, and NE.
PHARMACEUTICAL CHEMISTRY JOURNAL
(2023)
Editorial Material
Surgery
Shanel Normandin, Tyler Safran, Ryan Mitchell, Peter Davison, Sebastian Winocour, Edward Reece, Mirko S. S. Gilardino, Liqin Xu, Joshua Vorstenbosch
PLASTIC AND RECONSTRUCTIVE SURGERY
(2023)
Article
Chemistry, Multidisciplinary
Jinchai Xu, Fangfang Qu, Bihe Shen, Zhenxiong Huang, Xiaoli Li, Haiyong Weng, Dapeng Ye, Renye Wu
Summary: In this study, a portable rapid non-destructive detection device integrating visible/short-wave and long-wave near-infrared spectroscopy was developed to detect tea polyphenol content in fresh tea leaves. The device achieved better prediction performance by fusing spectral data and extracted sensitive spectral wavebands for tea polyphenols. This device provides effective technical support for tea breeding and quality control.
APPLIED SCIENCES-BASEL
(2023)
Article
Genetics & Heredity
Hsien-Yu Fan, Wan-Yu Lin, Tzu-Pin Lu, Yun-Yu Chen, Justin BoKai Hsu, Sung-Liang Yu, Ta-Chen Su, Hung-Ju Lin, Yang-Ching Chen, Kuo-Liong Chien
Summary: This study used targeted next-generation sequencing to investigate the association between genetic variants and left ventricular mass, and identified candidate genes including CASQ2, COL5A1, and FXN. These findings provide important insights into the functional mechanisms of these genes and variants.
FRONTIERS IN GENETICS
(2023)